Abstract
Many genes and signalling pathways controlling cell proliferation, death and differentiation, as well as genomic integrity, are involved in cancer development. New techniques, such as serial analysis of gene expression and cDNA microarrays, have enabled measurement of the expression of thousands of genes in a single experiment, revealing many new, potentially important cancer genes1,2. These genome screening tools can comprehensively survey one tumor at a time; however, analysis of hundreds of specimens from patients in different stages of disease is needed to establish the diagnostic, prognostic and therapeutic importance of each of the emerging cancer gene candidates. Here we have developed an array-based high-throughput technique that facilitates gene expression and copy number surveys of very large numbers of tumors. As many as 1000 cylindrical tissue biopsies from individual tumors can be distributed in a single tumor tissue microarray. Sections of the microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array, and consecutive sections allow the rapid analysis of hundreds of molecular markers in the same set of specimens. Our detection of six gene amplifications as well as p53 and estrogen receptor expression in breast cancer demonstrates the power of this technique for defining new subgroups of tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
DeRisi, J. et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genet. 14, 457–460 (1996).
Zhang, L. et al. Gene expression profiles in normal and cancer cells. Science 276, 1268–1272 (1997).
Kallioniemi, O.P. et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl. Acad. Sci. USA. 89, 5321–5325 (1992).
Ried, T. Interphase cytogenetics and its role in molecular diagnostics of solid tumors. Am. J. Pathol. 152, 325–328 (1998).
Pauletti, C., Godolphin, W., Press, M.F. & Slamon, D.J. Detection and quantitation of HER-2/neu gene amplification in human breastcancer archival material using fluorescence in situ hybridization. Oncogene 13, 63–72 (1996).
Slamon, D.J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
Barbareschi, M. et al. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with dinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int. J Cancer 74, 171–174 (1997).
Persons, D.L., Borelli, K.A. & Hsu, P.H. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod. Pathol. 10, 720–727 (1997).
Guan, X.Y., Meltzer, P.S., Dalton, W.S. & Trent, J.M. Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. Nature Genet. 8, 155–161 (1994).
Muleris, M., Almeida, A., Gerbault-Seureau, M., Malfoy, B. & Dutrillaux, B. Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chrom. Cancer 10, 160–170 (1994).
Barlund, M. et al. Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chrom. Cancer 20, 372–376 (1997).
Tanner, M.M. et al. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res. 54, 4257–4260 (1994).
Noben-Trauth, K. et al. Mybl2 (Bmyb) maps to mouse chromosome 2 and human chromosome 20q13.1. Genomics 35, 610–612 (1996).
Borg, A. et al. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br. J. Cancer 63, 136–142 (1991).
Courjal, F. et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 57, 4360–4367 (1997).
Allred, D.C. et al. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch. Surg. 125, 107–113 (1990).
Molino, A. et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res. Treat. 45, 241–249 (1997).
Battifora, H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab. Invest. 55, 244–248 (1986).
Battifora, H. & Mehta, P. The checkerboard tissue block. An improved multitissue control block. Lab. Invest. 63, 722–724 (1990).
Press, M.F., Hung, G., Godolphin, W. & Slamon, D.J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potentialsource of error in immunohistochemical studies of oncogene expression. Cancer Res. 54, 2771–2777 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kononen, J., Bubendorf, L., Kallionimeni, A. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844–847 (1998). https://doi.org/10.1038/nm0798-844
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0798-844
This article is cited by
-
Anaplastic lymphoma kinase expression in PDGFRA-mutated gastrointestinal stromal tumors probably correlates with poor prognosis
World Journal of Surgical Oncology (2023)
-
MDM2 amplification is rare in gastric cancer
Virchows Archiv (2023)
-
Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers
Journal of Cancer Research and Clinical Oncology (2023)
-
Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid
Scientific Reports (2023)
-
Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder
International Urology and Nephrology (2023)